SCHEMBL2249206

SCHEMBL2249206

O=C(O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(Br)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCGR P47871 17/20 0.53
GIPR P48546 8/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C8 P10632 1/20 0.53
CYP2C9 P11712 1/20 0.53
KCNH2 Q12809 1/20 0.53
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
MEN1 O00255 1/20 0.45
GALR3 O60755 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
NPY1R P25929 1/20 0.45
STAT3 P40763 1/20 0.45
NPY2R P49146 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385617 0.87 GCGR (0.47) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL3385621 0.87 GCGR (0.55) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2252981 0.85 GCGR (0.64) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2251804 0.85 GCGR (0.75) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL13003183 0.82 GCGR (0.64) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2257761 0.81 GCGR (0.61) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL3245420 0.78 GCGR (0.52) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL3383384 0.77 GCGR (0.62) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL4276462 0.76 GCGR (0.63) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2253902 0.75 GCGR (0.83) GCGRGIPRCYP3A4CYP2C8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989475-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2011-08-02 US disclosed
EP-1590336-B1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2010-12-01 EP disclosed
US-20090215825-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2009-08-27 US disclosed
US-7572922-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-08-11 US disclosed
US-20060084681-A1 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK SHARP & DOHME LLC 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215825-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GLP1R, GCGR, GPR119 GCGR 2/4885GIPR 4/4885CYP3A4 325/4885
US-20060084681-A1 Substituted pyrazoles, compositions containing such compounds and methods of use GLP1R, GCGR, GPR119 GCGR 2/4885GIPR 4/4885CYP3A4 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.